Detalhe da pesquisa
1.
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Cancer Res
; 76(15): 4504-15, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27312529
2.
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
Cancer Discov
; 5(12): 1271-81, 2015 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26432108
3.
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Cancer Discov
; 5(4): 358-67, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25673644
4.
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
Cancer Discov
; 4(4): 452-65, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24444711
5.
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.
Cancer Cell
; 23(1): 121-8, 2013 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23245996
6.
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Sci Transl Med
; 5(196): 196ra98, 2013 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-23903755